SMT201600050B - Mezzi e metodi per trattare il dlbcl - Google Patents

Mezzi e metodi per trattare il dlbcl

Info

Publication number
SMT201600050B
SMT201600050B SM201600050T SM201600050T SMT201600050B SM T201600050 B SMT201600050 B SM T201600050B SM 201600050 T SM201600050 T SM 201600050T SM 201600050 T SM201600050 T SM 201600050T SM T201600050 B SMT201600050 B SM T201600050B
Authority
SM
San Marino
Prior art keywords
dlbcl
treat
methods
Prior art date
Application number
SM201600050T
Other languages
English (en)
Italian (it)
Inventor
Gerhald Zugmaier
Dirk Nagorsen
Juergen Scheele
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45023802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600050(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of SMT201600050B publication Critical patent/SMT201600050B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
SM201600050T 2010-10-27 2016-02-17 Mezzi e metodi per trattare il dlbcl SMT201600050B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40710710P 2010-10-27 2010-10-27
PCT/EP2011/068851 WO2012055961A1 (en) 2010-10-27 2011-10-27 Means and methods for treating dlbcl

Publications (1)

Publication Number Publication Date
SMT201600050B true SMT201600050B (it) 2016-04-29

Family

ID=45023802

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600050T SMT201600050B (it) 2010-10-27 2016-02-17 Mezzi e metodi per trattare il dlbcl

Country Status (31)

Country Link
US (2) US9192665B2 (ja)
EP (3) EP3018145B1 (ja)
JP (3) JP5997168B2 (ja)
KR (1) KR101889995B1 (ja)
CN (2) CN105251003B (ja)
AU (1) AU2011322581B2 (ja)
CA (1) CA2815119C (ja)
CL (1) CL2013001138A1 (ja)
CR (1) CR20130245A (ja)
CY (3) CY1117155T1 (ja)
DK (3) DK2632954T4 (ja)
EA (1) EA032139B1 (ja)
ES (3) ES2563439T5 (ja)
HK (1) HK1188229A1 (ja)
HR (2) HRP20151444T4 (ja)
HU (3) HUE027678T2 (ja)
IL (3) IL225924A (ja)
LT (2) LT3018145T (ja)
MA (1) MA34619B1 (ja)
ME (1) ME02311B (ja)
MY (1) MY163057A (ja)
NZ (2) NZ609201A (ja)
PL (3) PL3018145T3 (ja)
PT (3) PT3412687T (ja)
RS (3) RS60094B1 (ja)
SG (1) SG189869A1 (ja)
SI (3) SI2632954T2 (ja)
SM (1) SMT201600050B (ja)
TR (1) TR201808019T4 (ja)
UA (1) UA111175C2 (ja)
WO (1) WO2012055961A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114115A1 (de) 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
PL3018145T3 (pl) * 2010-10-27 2018-09-28 Amgen Research (Munich) Gmbh Środki i sposoby leczenia chłoniaka rozlanego z dużych komórek B (DLBCL)
SG190174A1 (en) 2010-11-10 2013-07-31 Amgen Res Munich Gmbh Prevention of adverse effects caused by cd3 specific binding domains
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP3057994B1 (en) * 2013-10-15 2020-09-23 The Scripps Research Institute Peptidic chimeric antigen receptor t cell switches and uses thereof
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
ES2819976T5 (es) 2015-05-18 2024-02-23 Tcr2 Therapeutics Inc Composiciones y usos médicos para la reprogramación de TCR con proteínas de fusión
WO2018014001A1 (en) 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP3445787B1 (en) 2016-10-07 2020-12-02 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
WO2018075807A1 (en) 2016-10-19 2018-04-26 California Institute For Biomedical Research Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018098365A2 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
EP3962490A4 (en) * 2019-05-03 2023-01-25 Kite Pharma, Inc. CHEMERA ANTIGEN RECEPTOR IMMUNOTHERAPY ADMINISTRATION METHODS
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
MX2023006538A (es) * 2020-12-04 2023-08-08 Morphosys Ag Terapia combinada de anticuerpo anti cúmulo de diferenciación 19 (cd19).
MX2023008949A (es) 2021-01-28 2023-10-23 Regeneron Pharma Composiciones y metodos para tratar el sindrome de liberacion de citocinas.
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
EP1071752B1 (en) 1998-04-21 2003-07-09 Micromet AG CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
EP1691833B1 (en) 2003-11-28 2010-03-03 Micromet AG Compositions comprising polypeptides
PL1853718T3 (pl) 2005-02-15 2016-01-29 Univ Duke Przeciwciała anty-CD19 i zastosowania w onkologii
WO2006114115A1 (de) * 2005-04-26 2006-11-02 Trion Pharma Gmbh Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
JP5442998B2 (ja) 2005-12-16 2014-03-19 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 腫瘍性疾患を処置するための手段および方法
PL2066349T3 (pl) 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
ME03480B (me) * 2008-11-07 2020-01-20 Amgen Res Munich Gmbh Tretiranje akutne limfoblastne leukemije
PT2493503E (pt) * 2009-10-27 2015-11-12 Amgen Res Munich Gmbh Regime de dosagem para administração de um anticorpo biespecífico cd19xcd3
PL3018145T3 (pl) * 2010-10-27 2018-09-28 Amgen Research (Munich) Gmbh Środki i sposoby leczenia chłoniaka rozlanego z dużych komórek B (DLBCL)

Also Published As

Publication number Publication date
ME02311B (me) 2016-06-20
HRP20151444T4 (hr) 2021-08-20
JP2018039838A (ja) 2018-03-15
CA2815119A1 (en) 2012-05-03
CY1120227T1 (el) 2018-12-12
MY163057A (en) 2017-08-15
CY1123251T1 (el) 2021-10-29
SG189869A1 (en) 2013-06-28
IL225924A0 (en) 2013-06-27
EP2632954A1 (en) 2013-09-04
LT3412687T (lt) 2020-07-27
EA201390387A1 (ru) 2013-10-30
PT3412687T (pt) 2020-04-03
AU2011322581B2 (en) 2015-04-23
NZ609201A (en) 2015-01-30
RS54525B1 (en) 2016-06-30
ES2675299T3 (es) 2018-07-10
NZ719768A (en) 2021-07-30
PT2632954E (pt) 2016-02-03
ES2563439T3 (es) 2016-03-15
SI2632954T2 (sl) 2021-11-30
IL260774B (en) 2019-02-28
US20130287778A1 (en) 2013-10-31
WO2012055961A1 (en) 2012-05-03
EP3018145A1 (en) 2016-05-11
HUE037786T2 (hu) 2018-09-28
AU2011322581A1 (en) 2013-05-09
RS57260B1 (sr) 2018-08-31
EP2632954B2 (en) 2021-07-07
HK1188229A1 (en) 2014-04-25
CL2013001138A1 (es) 2014-11-14
EP3018145B1 (en) 2018-04-04
UA111175C2 (uk) 2016-04-11
HRP20151444T1 (hr) 2016-01-29
CA2815119C (en) 2023-01-10
DK3018145T3 (en) 2018-05-28
PL2632954T5 (pl) 2021-11-02
HUE048639T2 (hu) 2020-08-28
JP5997168B2 (ja) 2016-09-28
JP6522722B2 (ja) 2019-05-29
CN105251003A (zh) 2016-01-20
ES2563439T5 (es) 2022-02-04
DK3412687T3 (da) 2020-05-11
DK2632954T4 (da) 2021-08-09
SI3018145T1 (en) 2018-08-31
LT3018145T (lt) 2018-05-10
SI2632954T1 (sl) 2016-02-29
MA34619B1 (fr) 2013-10-02
CN103459425A (zh) 2013-12-18
CN103459425B (zh) 2015-11-25
RS60094B1 (sr) 2020-05-29
JP2013540799A (ja) 2013-11-07
EP2632954B1 (en) 2015-11-25
CN105251003B (zh) 2019-08-02
ES2787044T3 (es) 2020-10-14
PL2632954T3 (pl) 2016-05-31
PT3018145T (pt) 2018-05-17
IL256110A (en) 2018-02-28
EA032139B1 (ru) 2019-04-30
SI3412687T1 (sl) 2020-07-31
HRP20180882T1 (hr) 2018-07-27
EP3412687A1 (en) 2018-12-12
DK2632954T3 (en) 2016-02-01
PL3018145T3 (pl) 2018-09-28
NZ701715A (en) 2016-05-27
US10696744B2 (en) 2020-06-30
CR20130245A (es) 2013-09-20
US20160208001A1 (en) 2016-07-21
US9192665B2 (en) 2015-11-24
KR101889995B1 (ko) 2018-08-20
TR201808019T4 (tr) 2018-06-21
EP3412687B1 (en) 2020-03-18
KR20140019298A (ko) 2014-02-14
CY1117155T1 (el) 2017-04-05
JP6254220B2 (ja) 2017-12-27
HUE027678T2 (en) 2016-11-28
IL225924A (en) 2017-12-31
PL3412687T3 (pl) 2020-07-27
IL256110B (en) 2018-08-30
JP2016164192A (ja) 2016-09-08
RS54525B2 (sr) 2021-08-31

Similar Documents

Publication Publication Date Title
SMT201600050B (it) Mezzi e metodi per trattare il dlbcl
BR112013007499A2 (pt) piridazinonas - métodos de criação e usos
BR112012017441A2 (pt) compostos e métodos
DK2542920T3 (da) Fremgangsmåde til lokal attribut sammenligning i seismisk behandling
BR112012015988A2 (pt) método
BR112012027159A2 (pt) estrutura e método
DK2613884T3 (da) Findelingsindretning
FR2955040B1 (fr) Pre-broyeur ou pre-dechiqueteur
BR112013009024A2 (pt) método
BR112012023891A2 (pt) método
FR2964937B1 (fr) Triporteur et direction de triporteur
CO6940387A2 (es) Aparato y método de chancado
FI20100404A0 (fi) Yhteysalus
BR112012033340A2 (pt) conjunto de trituração
BR112012033000A2 (pt) método
DK2568829T3 (da) Pasteuriseringsanlæg med reguleret sprøjtemængde
BR112013013441A2 (pt) composição de adesivo-engomadura e métodos relacionados
BR112013014731A2 (pt) tamavidina modificada
FIU20100501U0 (fi) Yhteysalus
DK2380545T3 (da) Terapi-indretning
TH1401000560B (th) วิธีการ และอุปกรณ์สำหรับการบำบัดเชิงกล หรือเชิงกล-ชีวภาพสำหรับของเสีย
IT1400814B1 (it) Capovolgitore
ITPD20090073U1 (it) Dispositivo per magnetoterapia
ITMI20112024A1 (it) Apparecchio spazza pavimenti
UY3960Q (es) Configuración aplicada en licuadora